Comgest Global Investors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cognizant
CTSH
|
+$138M |
| 2 |
Autohome
ATHM
|
+$45.2M |
| 3 |
Baidu
BIDU
|
+$40.3M |
| 4 |
Eli Lilly
LLY
|
+$17M |
| 5 |
CBPO
China Biologic Products Holdings, Inc.
CBPO
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$32M |
| 2 |
Becton Dickinson
BDX
|
+$18.2M |
| 3 |
Telefônica Brasil
VIV
|
+$4.48M |
| 4 |
Dollar General
DG
|
+$4.07M |
| 5 |
Apple
AAPL
|
+$4.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 38.67% |
| 2 | Technology | 32.91% |
| 3 | Consumer Staples | 8.82% |
| 4 | Healthcare | 7.84% |
| 5 | Consumer Discretionary | 6.66% |
Similar funds
Comgest Global Investors's Q2 2017 Portfolio in Review
As of Q2 2017, Comgest Global Investors held 58 positions worth $4.04B, up 8.3% from $3.73B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Comgest Global Investors deployed $211M of net new capital in Q2 2017, opening 4 new positions and adding to 25 existing holdings. Its largest new stake was China Biologic Products Holdings, Inc.: 151,603 shares worth $17.1M.
By sector, the portfolio is most concentrated in Communication Services at 39% of assets, down from 39% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was NetEase, an estimated $32M trimmed.
- Comgest Global Investors's largest Q2 2017 buy was China Biologic Products Holdings, Inc.: 151,603 shares worth $17.1M.
- Comgest Global Investors added most to Cognizant in Q2 2017, an estimated $138M increase.
- Comgest Global Investors's biggest Q2 2017 reduction was NetEase, cutting an estimated $32M.
- Comgest Global Investors fully exited Dollar General in Q2 2017, selling an estimated $4.07M.
- Comgest Global Investors's ten largest holdings make up 78% of its $4.04B portfolio in Q2 2017.
- Comgest Global Investors opened 4 new positions and closed 2 in Q2 2017.
- Comgest Global Investors's portfolio value rose 8.3% quarter-over-quarter to $4.04B.
Based on Comgest Global Investors's 13F filing for Q2 2017, filed 9 Aug 2017.